economybharat.com

We Can Cover You
Click here
Facebook Youtube Instagram Linkedin
13
13

Nemolizumab

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis OG_NewsReleaseCompanyLogo_92873.jpg

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

creativebharatgroup@gmail.com December 14, 2024
Zug, Switzerland:   Ad hoc announcement pursuant to Art. 53 LR   ...
Read More Read more about Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union OG_NewsReleaseCompanyLogo_92866.jpg

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

creativebharatgroup@gmail.com December 13, 2024
Zug, Switzerland:   Atopic dermatitis is a common, chronic, and flaring inflammatory...
Read More Read more about CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis OG_NewsReleaseCompanyLogo_92678.jpg

Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis

creativebharatgroup@gmail.com November 29, 2024
Zug, Switzerland:   Full results from the phase III OLYMPIA 1 trial...
Read More Read more about Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis